Ayesha Younas

Dr. Ayesha Younas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Carbohydrate Polymers
Verified
Journal Article
Closed access
AYAyesha Younas
Ayesha Younas
ZDZhuolin Dong
Zhuolin Dong
ZHZiye Hou
Ziye Hou
Muhammad AsadMuhammad Asad
Muhammad Asad
MLMengru Li
Mengru Li
NZNan Zhang
Nan Zhang

7 April 2022 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
Muhammad AsadMuhammad Asad
Muhammad Asad
MAMuhammad Imran Anwar
Muhammad Imran Anwar
AAAnsar Abbas
Ansar Abbas
AYAyesha Younas
Ayesha Younas
SHSameer Hussain
Sameer Hussain
SKShabnam Khan
Shabnam Khan

5 February 2022 in Carbohydrate Polymers
Verified
Journal Article
Closed access
NZNan Zhang
Nan Zhang
LXLingping Xue
Lingping Xue
AYAyesha Younas
Ayesha Younas
FLFenfen Liu
Fenfen Liu
JSJunhong Sun
Junhong Sun
YZYongxing Zhao
Yongxing Zhao

10 December 2025 in Materials Today Bio
Verified
Journal Article
Open access
AYAyesha Younas
Ayesha Younas
SWShuanghu Wang
Shuanghu Wang
Muhammad AsadMuhammad Asad
Muhammad Asad
AMAbdullah Al Mamun
Abdullah Al Mamun
SMSaadat Majeed
Saadat Majeed
JXJian Xiao
Jian Xiao
Cancer nanomedicine has evolved from the 1995 landmark approval of Doxil® into a programmable platform of precision oncology. The field now progresses along a coherent continuum that begins with passive enhanced permeability and retention (EPR)-mediated tumor accumulation, advances to active ligand–receptor targeting, and culminates in stimuli-responsive carriers whose cargo is liberated only when triggered by endogenous (acidic pH, redox imbalance, elevated GSH, dysregulated enzymes, ROS) or exogenous (light, magnetic, ultrasound, X-ray, electric) cues intrinsic to the tumor microenvironment (TME). This review maps this continuum, highlighting how the integration of patient-specific multi-omics data with artificial intelligence (AI) is converting tumor heterogeneity into quantitative design rules for nanocarrier optimization, validated in patient-derived organoids. Despite over 15 FDA-approved cancer nanomedicines and a robust clinical pipeline, translation is impeded by biological barriers, protein corona-mediated toxicity, manufacturing scalability issues, and a fragmented regulatory landscape. To bridge this bench-to-bedside chasm, we propose a convergent roadmap: safe-by-design engineering, quality-by-design modular manufacturing, and AI-guided digital twins coupled with micro/nano-robotic delivery for real-time, adaptive dosing. Realizing this vision will transform nanomedicine from an empirical carrier technology into a patient-calibrated, closed-loop therapeutic engine, cementing its role as the frontline of precision oncology.

2 February 2022 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
HSHongtao Shang
Hongtao Shang
AYAyesha Younas
Ayesha Younas
NZNan Zhang
Nan Zhang

4 September 2025 in Phytomedicine
Verified
Journal Article
Open access
YLYunxiao Liu
Yunxiao Liu
XDXiaomei Ding
Xiaomei Ding
AYAyesha Younas
Ayesha Younas
XSXiaoning Sun
Xiaoning Sun
XNXiaofen Ni
Xiaofen Ni
CSChuxiao Shao
Chuxiao Shao
Non-alcoholic fatty liver disease (NAFLD) and depression represent two highly prevalent medical conditions often presenting concurrently. However, currently available pharmacological treatments rarely target both disorders simultaneously. Xiaoyao San (XYS), a traditional herbal formulation from Chinese medicine, has been clinically effective in addressing NAFLD and depressive symptoms, although its precise therapeutic mechanisms remain poorly understood. This study aimed to investigate the underlying mechanisms of XYS in managing comorbid NAFLD and depression by employing network pharmacology (NP) and multi-omics methodologies. A chronic restraint stress (CRS)-induced NAFLD rat model was constructed to simulate the disease conditions. The efficacy of XYS treatment was evaluated through behavioral assessments, histopathological liver examination, biochemical analyses, and measurements of inflammatory and oxidative stress (OS) biomarkers. Further, NP combined with metabolomic and proteomic techniques was applied to uncover pivotal targets and pathways, with subsequent validation via Western blotting (WB). XYS improved depression-like behaviors, reduced hepatic lipid deposition, and lowered levels of hepatic enzymes, blood lipids, and blood glucose. It also attenuated inflammatory and OS responses. Multi-omics analysis identified the PPARα/HMOX1/GPX4 axis as a key target. XYS modulated this pathway to inhibit ferroptosis and reduce hepatic iron accumulation. Specifically, XYS upregulated PPARα and GPX4 expression, downregulated HMOX1 expression, and decreased hepatic iron levels, alleviating both NAFLD and depression. XYS exerts therapeutic effects on NAFLD and depression through multi-target regulation, primarily by modulating the PPARα/HMOX1/GPX4 axis to inhibit ferroptosis. This study provides a novel mechanistic basis for the dual therapeutic efficacy of XYS.